Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.
You may also be interested in...
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.
AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says
Even though both components are already marketed, firm might have to do another study for fixed-dose combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.
Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?
Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.